Skip to content

Friday, July 24, 2026

Latest:

High stakes, thin data: Why cardiovascular research must do better for hemodialysis patients
Researchers uncovered a novel pathway that causes epilepsy
Welcome new residents and fellows!
Space to clinic: How TRISH helped advance ultrasound simulation with Level Ex
Turning the tables on chemotherapy resistance: LIG1 loss exposes a therapeutic vulnerability in triple-negative breast cancer

Home
Momentum
From The Labs
- About From the Labs
- Follow From The Labs on Twitter
Policywise
- About PolicyWise
- Follow @BCMEthics on Twitter
The Stitch
- About The Stitch
Progress Notes
bcm.edu

ACTL6A

A new mechanism of cisplatin resistance in cancer, and how to reverse it

April 22, 2021 ACTL6A, cancer resistance to therapy, cisplatin, DNA repair, epigenetic chromatin remodeling, panobinostat, Research

ACLT6A overexpression confers cancer cells resistance to cisplatin, and researchers found a way to reverse it.

From the Labs: Image of the Month

From the Labs: Tau travels between neurons

Healthy Habits: A DOC-umentary Series

Archives

Archives

Search

©1998 - 2023 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951